PR006 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 1 |
127. Frontotemporal lobar degeneration
Clinical trials : 89 / Drugs : 104 - (DrugBank : 33) / Drug target genes : 40 - Drug target pathways : 117
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04408625 (ClinicalTrials.gov) | November 9, 2020 | 21/5/2020 | Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) | A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN) | Frontotemporal Dementia | Biological: PR006;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone;Drug: Rituximab | Prevail Therapeutics | Eli Lilly and Company | Recruiting | 30 Years | 80 Years | All | 15 | Phase 1/Phase 2 | United States;Australia;Spain |